At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
Etrasimod 1 mg +2 moredrug
Likely dose
Etrasimod 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Etrasimod 1 mg, Etrasimod 2 mg, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 140 participants across 38 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
Primary CompletionSep 2020
Study CompletionOct 2021
TodayJul 2026
First PostedNov 14, 2019
Enrollment StartOct 4, 2019
Primary CompletionSep 9, 2020
Study CompletionOct 11, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.6 years ago
Interventions
Etrasimod 1 mgdrug
Etrasimod 1 mg tablet taken by mouth, once daily
Etrasimod 2 mgdrug
Etrasimod 2 mg tablet taken by mouth, once daily.
Etrasimod matching placebodrug
Etrasimod matching placebo tablet by mouth, once daily.